Effect of Short-term Dutasteride Therapy on Prostate Vascularity in Patients With Benign Prostatic Hyperplasia: A Pilot Study

Kravchick, Sergey; Cytron, Shmuel; Mamonov, Alla; Peled, Ronit; Linov, Lina

doi:10.1016/j.urology.2008.08.461

Cited by 38 publications

(47 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some investigators [14,15,24] reported that preoperative short-term (2-4 weeks) dutasteride use could not reduce blood loss during or after TURP. Kravchick et al [29] found that 6 weeks of dutasteride treatment may be enough to reduce prostate tissue vascularity in the periurethral area proximal to the verumontanum. So a minimal treatment course of 6 weeks might be considered necessary before surgery.…”

Section: Discussionmentioning

confidence: 99%

A Systematic Review and Meta-Analysis of the Effects on Dutasteride Treatment for Reducing Surgical Blood Loss during Transurethral Resection of the Prostate

Ren

Lai²,

Jiang³

et al. 2016

Urol Int

View full text Add to dashboard Cite

Objective: This systematic review and meta-analysis were performed to evaluate the efficacy of preoperative dutasteride treatment for reducing surgical blood loss in patients undergoing transurethral resection of the prostate (TURP). Methods: A systematic search was performed from the electronic databases including PubMed, EMBASE, and Cochrane Library by May 2016. We followed the search strategy based on Preferred Reporting Items for Systematic Reviews and Meta-analysis statement when examining the literature. Identified articles were strictly appraised for quality and relevance. Results: Five randomized controlled trials (RCTs) and 5 retrospective cohort studies involving 1,022 patients with benign prostate hyperplasia were analyzed based on the inclusion criteria. Pooled analysis revealed that preoperative treatment with dutasteride had a significantly smaller decrease in hemoglobin (weighted mean difference [WMD] -0.47, 95% CI -0.70 to -0.24, p < 0.0001) and hematocrit levels (WMD -1.03, 95% CI -1.73 to -0.33, p = 0.004); However, no signiﬁcant difference has been found in terms of the total blood loss during TURP and blood loos per gram of resected prostatic tissue, the weight of resected prostate tissue, the microvessel density of the prostate, and the transfusion rate between the dutasteride and the control group. Conclusions: This systematic review and meta-analysis indicate that preoperative treatment with dutasteride could reduce surgical bleeding during TURP, but the findings of this study should be further confirmed by well-designed prospective RCTs with a larger patient series.

show abstract

Section: Discussionmentioning

confidence: 99%

A Systematic Review and Meta-Analysis of the Effects on Dutasteride Treatment for Reducing Surgical Blood Loss during Transurethral Resection of the Prostate

Ren

Lai²,

Jiang³

et al. 2016

Urol Int

View full text Add to dashboard Cite

show abstract

“…11 Kravchick demonstrated that 6 weeks of treatment with dutasteride reduced prostatic vascularity, especially in the periurethral area. 1 Based on these evidences, we attempted to evaluate if pretreatment with dutasteride (0.5 mg/day) for 6 weeks before TURP could reduce surgical bleeding. None of the previous authors had used dutasteride for 6 weeks before surgery.…”

Section: Discussionmentioning

confidence: 99%

“…Dutasteride, (which acts as an inhibitor of type 1 and 2 isoenzymes of 5-alpha-reductase inhibitors ), was found to reduce prostate tissue vascularity within 6 weeks of therapy. 1 In this study, we tried to evaluate whether pretreatment with dutasteride can reduce the surgical blood loss.…”

Section: Introductionmentioning

confidence: 99%

Transurethral Resection of Prostate and the Role of Pharmacological Treatment with Dutasteride in Decreasing Surgical Blood Loss

Pastore¹,

Mariani

Barrese

et al. 2013

Journal of Endourology

View full text Add to dashboard Cite

show abstract

“…Supporting this hypothesis, withdrawal of androgenic signaling by AR antagonists (e.g., flutamide and bicalutamide) and inhibitors of steroid metabolism (e.g., finasteride and dutasteride) reduced hematuria during prostate surgery and in patients with benign prostatic hyperplasia (BPH) (18,31,59,73,74,95). More recently, two clinical studies (4,52) showed that combination therapy with bicalutamide-goserelin (a gonadotropin-releasing hormone agonist) and dutasteride (inhibitor of 5␣-reductase isoenzyme types 1 and 2) induced profound vascular collapse in human CaP patients and reduced prostatic tissue vascularity. Our group demonstrated that acute prostate vascular involution was induced by androgen withdrawal in primary xenografts of benign or malignant human prostate tissue transplanted into severe combined immunodeficiency mice in which the vasculature was of human origin (29).…”

Section: Androgen Action On Endothelium Of the Prostate And Prostate mentioning

confidence: 99%

Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate

Godoy

Chung

Montecinos

et al. 2013

American Journal of Physiology-Endocrinology and Metabolism

View full text Add to dashboard Cite

Forty years ago, Judah Folkman (Folkman. N Engl J Med 285: 1182-1186, 1971 proposed that tumor growth might be controlled by limiting formation of new blood vessels (angiogenesis) needed to supply a growing tumor with oxygen and nutrients. To this end, numerous "antiangiogenic" agents have been developed and tested for therapeutic efficacy in cancer patients, including prostate cancer (CaP) patients, with limited success. Despite the lack of clinical efficacy of lead antiangiogenic therapeutics in CaP patients, recent published evidence continues to support the idea that prostate tumor vasculature provides a reasonable target for development of new therapeutics. Particularly relevant to antiangiogenic therapies targeted to the prostate is the observation that specific hormones can affect the survival and vascular function of prostate endothelial cells within normal and malignant prostate tissues. Here, we review the evidence demonstrating that both androgen(s) and vitamin D significantly impact the growth and survival of endothelial cells residing within prostate cancer and that systemic changes in circulating androgen or vitamin D drastically affect blood flow and vascularity of prostate tissue. Furthermore, recent evidence will be discussed about the expression of the receptors for both androgen and vitamin D in prostate endothelial cells that argues for direct effects of these hormone-activated receptors on the biology of endothelial cells. Based on this literature, we propose that prostate tumor vasculature represents an unexplored target for modulation of tumor growth. A better understanding of androgen and vitamin D effects on prostate endothelial cells will support development of more effective angiogenesis-targeting therapeutics for CaP patients.androgens; androgen receptor; vitamin D; endothelium; prostate cancer

show abstract

Effect of Short-term Dutasteride Therapy on Prostate Vascularity in Patients With Benign Prostatic Hyperplasia: A Pilot Study

Cited by 38 publications

References 16 publications

A Systematic Review and Meta-Analysis of the Effects on Dutasteride Treatment for Reducing Surgical Blood Loss during Transurethral Resection of the Prostate

A Systematic Review and Meta-Analysis of the Effects on Dutasteride Treatment for Reducing Surgical Blood Loss during Transurethral Resection of the Prostate

Transurethral Resection of Prostate and the Role of Pharmacological Treatment with Dutasteride in Decreasing Surgical Blood Loss

Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate

Contact Info

Product

Resources

About